Deutsches Leukämie-Studienregister
Studie: DASFREE

Gesamtübersicht
Öffentlicher Titel Evaluationsstudie zu Therapieabbruch von Dasatinib in Patienten mit stabiler CMR in CP-CML
Wissenschaftl. Titel Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
Kurztitel DASFREE
Studiengruppe NN
Studienart einarmig, offen
Erkrankung Chronische myeloische Leukämie (CML) - Chronische Phase
Molekularer Marker BCR-ABL
Alter >= 18 Jahre
Status Rekrutierung beendet
Beginn der Rekrutierung 01.09.2014
Kurzprotokoll Kurzprotokoll
Anmerkung Primary Outcome Measures: MMR rate at 12 months [ Time Frame: At 12 months after Dasatinib discontinuation ] [ Designated as safety issue: No ] Major Molecular Response (MMR) rate at 12 months is the proportion of subjects who maintain MMR at 12 months after Dasatinib discontinuation without re-starting Dasatinib treatment in the enrolled subjects in the study Secondary Outcome Measures: Event-free survival (EFS) after Dasatinib discontinuation [ Time Frame: At 12 months after Dasatinib discontinuation ] EFS is defined as survival with no molecular relapse, including no loss of MMR Relapse-free survival (RFS) after Dasatinib discontinuation [ Time Frame: At 6, 18, 24 months and every 6 months thereafter up to 5 years ] [ Designated as safety issue: No ] Relapse is defined as any of the following events while a subject is on study: the loss of MMR, Complete Cytogenetic Response (CCyR), Complete Hematologic Response (CHR) or progression to advanced/blastic phase. RFS is defined as the time from Dasatinib treatment discontinuation to the date of relapse Assessment of BCR-ABL kinetics for subjects who experience loss of Complete Molecular Response (CMR) but not MMR [ Time Frame: Monthly in the first year and every 3 months thereafter up to 5 years ] Assessment of BCR-ABL kinetics in subjects in CMR or less with measurable levels [ Time Frame: Monthly in the first year and every 3 months thereafter up to 5 years ] Rate of transformation to AP/BC [ Time Frame: Up to 5 years or death date ] [ Designated as safety issue: No ] Accelerated Phase (AP) is defined as Blasts in Peripheral Blood (PB) or Bone Marrow (BM) 15-29%; Blast+promyelocytes >=30% with blasts < 30% or Additional Chromosomal Abnormalities (ACA) in Ph+ cells (clonal progression), or basophils in blood >= 20% or platelets <100 x 10(9)/L unrelated to therapy Blastic Phase or Crisis (BP/BC) is defined as Blasts in PB or BM >=30%, or extramedullary blast cell involvement (with the exception of spleen and liver) Progression Free Survival (PFS) [ Time Frame: Up to 5 years or death date ] [ Designated as safety issue: No ] Progression-free survival (PFS) is defined as overall survival plus the additional events progression to accelerated phase or blast crisis Rate of transformation to OS [ Time Frame: Up to 5 years or death date ] [ Designated as safety issue: No ] Overall survival (OS) is defined as the time between first dose date and death date
erstellt 24.09.2014 Hanna Ebert
geändert 14.11.2016 Eva-Maria Ableidinger
© Informationszentrum im Kompetenznetz Leukämien | Ohne Gewähr für Richtigkeit oder Vollständigkeit | www.kompetenznetz-leukaemie.de | info@kompetenznetz-leukaemie.de